Literature DB >> 17294139

The role of fibrinolytic system in no-reflow after stenting with and without predilation in patients with acute coronary syndromes: fibrinolysis and no-reflow after coronary stenting.

Sabri Demircan1, Mustafa Yazici, Cavid Hamiseyev, Gunnur Demircan, Sevinc Sultansuyu, Erdogan Yasar, Mahmut Sahin.   

Abstract

BACKGROUND: No-reflow developed after coronary revascularization is an independent predictor of in-hospital mortality and poor clinical outcome. In this study, we investigated the difference between direct stenting and stenting with predilation, regarding to development of no-reflow in patients with acute coronary syndromes (ACS) and the role of fibrinolytic system in that phenomenon.
METHODS: Fifty eight patients with the diagnosis of ACS in whom percutaneous coronary intervention (PCI) was applied were included in study. Patients were divided into two groups according to stent application with and without predilation. Pre- and post-intervention corrected TIMI frame counts (cTFC) were calculated. Post-PCI plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), plasminogen and D-Dimer levels were measured.
RESULTS: Pre-intervention cTFC values were similar between stenting with and without predilation groups (P > 0.05). There was a significant decrease in post-intervention cTFC values in both groups (P < 0.002 and P < 0.05, respectively). But, there was no significant difference between post-intervention cTFC values of the groups, regardless to stent implantation techniques. (P > 0.05). In patients having high cTFC values compared with having low cTFC values; PAI-1 (P = 0.002), tPA (P = 0.015), plasminogen (P = 0.040) and D-dimer (P = 0.049) levels were significantly higher. Also, significant relationship was determined between cTFC and PAI-1, tPA, plasminogen, D-dimer levels (P values 0.003, <0.05, <0.05, and <0.002, respectively).
CONCLUSIONS: Results of this study indicated an important role of increased fibrinolytic activity in development of no-reflow phenomenon after PCI. We didn't observe any differences between direct stenting and stenting with predilation according to the occurrence of no-reflow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294139     DOI: 10.1007/s11239-007-0012-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

1.  Pathology of coronary microembolisation and no reflow.

Authors:  E Falk; L Thuesen
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

2.  Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery.

Authors:  X L Ma; P S Tsao; G E Viehman; A M Lefer
Journal:  Circ Res       Date:  1991-07       Impact factor: 17.367

3.  Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators.

Authors:  R N Piana; W H Ahmed; B Chaitman; P Ganz; S Kinlay; J Strony; B Adelman; J A Bittl
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

4.  Variability in the analysis of coronary arteriograms.

Authors:  T A DeRouen; J A Murray; W Owen
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

5.  Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina.

Authors:  S Yazdani; A D Simon; L Kovar; W Wang; A Schwartz; L E Rabbani
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

Review 6.  Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon.

Authors:  A D Michaels; C M Gibson; H V Barron
Journal:  Am J Cardiol       Date:  2000-03-09       Impact factor: 2.778

Review 7.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

8.  Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.

Authors:  B H Strauss; H K Lau; K A Bowman; J Sparkes; R J Chisholm; M B Garvey; L L Fenkell; M K Natarajan; I Singh; J M Teitel
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

9.  Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis.

Authors:  H Sawa; C Lundgren; B E Sobel; S Fujii
Journal:  J Am Coll Cardiol       Date:  1994-12       Impact factor: 24.094

10.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

View more
  2 in total

1.  The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction.

Authors:  Ayhan Erkol; Vecih Oduncu; Burak Turan; Alev Kılıçgedik; Dicle Sırma; Gökhan Gözübüyük; Can Yücel Karabay; Ahmet Guler; Cihan Dündar; Kürşat Tigen; Selçuk Pala; Cevat Kırma
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

2.  Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study.

Authors:  Marin Pavlov; Vjeran Nikolić-Heitzler; Zdravko Babić; Milan Milošević; Krešimir Kordić; Ivana Ćelap; Vesna Degoricija
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.